Can GAVE Cause Iron Deficiency Anemia?
Yes, gastric antral vascular ectasia (GAVE) is a well-established cause of iron deficiency anemia through chronic gastrointestinal blood loss. 1, 2
Mechanism and Clinical Presentation
GAVE causes iron deficiency anemia through chronic, often occult bleeding from capillary-type vascular malformations in the gastric antrum. 2, 3 The bleeding is typically chronic rather than acute, manifesting primarily as progressive anemia rather than overt hematemesis or melena. 4, 2
Diagnostic Approach
- Upper endoscopy is the definitive diagnostic modality, revealing characteristic vascular ectasias in the gastric antrum with either a linear "watermelon stomach" pattern or diffuse distribution. 2
- GAVE should be suspected in patients with unexplained iron deficiency anemia, particularly those with associated conditions including cirrhosis, chronic kidney disease, systemic sclerosis, or other autoimmune diseases. 5, 6
- In systemic sclerosis patients specifically, GAVE is more common in those with anti-RNA polymerase III antibodies (71% vs 19%) and negative ANA (<1:80), suggesting these patients may warrant screening endoscopy. 6
Management Algorithm
Iron Replacement (First-Line for All Patients)
All patients with GAVE-related iron deficiency anemia require iron repletion therapy alongside definitive treatment. 1, 5
- Oral iron supplementation should be initiated first for mild-to-moderate iron depletion when tolerated. 1, 5
- Intravenous iron therapy is indicated when oral iron fails to replenish stores, in patients with ongoing bleeding despite oral supplementation, or in cases of severe anemia. 1, 5
Endoscopic Therapy (Definitive Treatment)
When iron replacement alone is inadequate, endoscopic therapy is the primary treatment modality. 1
The 2025 Canadian Association of Gastroenterology guideline establishes endoscopic band ligation (EBL) as the preferred first-line endoscopic treatment over thermal ablation methods. 5 This represents the most current high-quality evidence and supersedes older recommendations favoring argon plasma coagulation (APC).
EBL advantages over APC include: 5
- Fewer treatment sessions required (mean 2.6 vs 3.8 sessions)
- Greater hemoglobin increase (mean 0.6 g/dL higher)
- Reduced transfusion requirements (2.3 fewer packed red cell units)
- Favorable safety profile with only mild adverse events (nausea, vomiting, abdominal pain)
Argon plasma coagulation remains an acceptable alternative thermal method when EBL is unavailable or contraindicated. 1, 3
Important Caveats
- Endoscopic therapy should target active bleeding or high-risk lesions identified during diagnostic endoscopy, not routine systematic ablation of all visible ectasias. 5
- Recurrence is common: approximately 50% of patients experience recurrence at around 18 months after initial successful EBL treatment. 4 Patients requiring more pre-procedure blood transfusions have higher recurrence risk. 4
- Follow-up endoscopy should be scheduled based on clinical indicators of recurrence (declining hemoglobin, increased transfusion needs, return of anemia symptoms) rather than routine intervals. 5
Pharmacologic Therapy
No pharmacologic agents have proven efficacy as primary therapy for GAVE. 5 Tranexamic acid may be considered for mild bleeding given its low harm potential, though supporting evidence is limited. 5 This contrasts with other vascular bleeding conditions like hereditary hemorrhagic telangiectasia where systemic bevacizumab shows substantial benefit. 7
Treatment Failure
When both iron replacement and standard endoscopic therapy (EBL or APC) fail, radiofrequency ablation has shown promise as a salvage therapy in small case series, though this remains investigational. 8